Dalrada Financial Corporation Reports $20.3 Million Revenue and $24.7 Million Net Loss for Fiscal Year Ending June 30, 2025

Dalrada Financial Corporation reported a consolidated revenue of $20.3 million for the fiscal year ending June 30, 2025, marking a 2.3% increase from the previous year's revenue of $19.8 million. Despite this growth in revenue, the company experienced a net loss of $24.7 million, a decrease from the $29.2 million loss reported in the prior year. The improvement in net loss is attributed to a centralization of operational costs and a reduction in unproductive activities across its business segments.

The company's five primary divisions—Genefic, Dalrada Climate Technology, Dalrada Precision Manufacturing, Dalrada Technologies, and Dalrada Corporate—showed varied performance. Genefic's revenue decreased by 21.1% to $10.4 million, primarily due to a shift in its business model from high-volume, low-margin specialty pharmacy prescriptions to a lower-volume, high-margin model. In contrast, Dalrada Climate Technology saw a significant revenue increase of 188.2% to $8.1 million, driven by growth in its energy services and construction projects, particularly through its subsidiary Bothof Brothers Construction.

Operationally, Dalrada's total operating expenses decreased by 7.5% to $25.8 million, with notable reductions in corporate expenses. The company reported a goodwill impairment of $2.7 million, reflecting challenges in its Deposition Technologies segment. The overall employee headcount increased, particularly in the Genefic division, which saw a rise in compensation and benefits due to growth in its pharmacy operations.

Dalrada's strategic initiatives included the acquisition of Grand Entrances, a custom door and hardware retail store, which is expected to enhance its climate technology segment. The company also plans to focus on profitable subsidiaries while reducing investments in less promising areas. Looking ahead, Dalrada aims to improve its financial position through operational efficiencies, increased sales, and potential financing options, although it acknowledges substantial doubt about its ability to continue as a going concern without successful capital raising efforts.